UNSPSC 51314301: Acetaminophen/dextromethorphan/phenylephrine/pyrilamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE506. This VA Drug Class (RE506) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51314301 Acetaminophen/dextromethorphan/phenylephrine/pyrilamine is a Commodity code whose recent state and local activity does not align with the specific drug combination named in the code. The three most recent opportunities posted under this code involve naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer pharmaceutical prescriptions (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products broadly (Minnesota Multistate Cooperative Purchasing Alliance). The code appears to capture pharmaceutical procurement activity more generally rather than the acetaminophen-combination formulation its title suggests, and state and local buying under the code spans county health departments, state health agencies, and cooperative purchasing consortia. The scope of actual procurement includes both single-product buys (naloxone units) and multi-product framework agreements for generic pharmaceuticals and OTC items to be distributed across state and local facilities.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. The Texas Health and Human Services Commission posted an RFI (HHS0017013, due April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer pharmacy program, a preliminary market-intelligence vehicle designed to inform later formal procurement strategy. The Minnesota Department of Administration, through the MMCAP cooperative purchasing vehicle, issued an RFP (S1070000015802, due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with evaluations weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and smaller percentages on administrative compliance and EDI capability. The mismatch between the code's nominal scope and the recent opportunities suggests this code functions as a catch-all for pharmaceutical procurement rather than a category actively solicited for the specific combination product named.